AVN 12% Strides Linked TO Apple, Inc.

AVANIR Pharmaceuticals (AMEX:AVN) will be presenting at the 24th Annual JPMorgan Healthcare Conference on Wednesday, January 11, 2005, at 4:00 p.m. PT in San Francisco. AVANIR's President and Chief Executive Officer, Eric Brandt, will be presenting at the investor conference. The presentation will be available via a live webcast accessible through AVANIR's corporate website at www.avanir.com. To access the webcasts, log on to AVANIR's site fifteen minutes prior to the presentation to register and download any necessary audio software. Archived versions of the presentations will be available until February 12, 2006. AVANIR Pharmaceuticals is focused on developing and commercializing novel therapeutic products for the treatment of chronic diseases. AVANIR's product candidates address therapeutic markets that include central nervous system and cardiovascular disorders, inflammation, and infectious diseases. AVANIR previously announced positive results in the second of two required Phase III clinical trials of Neurodex(TM), an investigational new drug for the treatment of pseudobulbar affect. Additionally, AVANIR has initiated a Phase III clinical trial for Neurodex as a potential treatment for diabetic neuropathic pain, a second indication for Neurodex. AVANIR has active collaborations with two international pharmaceutical companies: Novartis International Pharmaceutical Ltd. for the treatment of inflammatory disease and AstraZeneca for the treatment of cardiovascular disease. The Company's first commercialized product, Abreva(R), is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores. Further information about AVANIR can be found at www.avanir.com. The information contained in this press release, including any forward-looking statements contained herein, should be reviewed in conjunction with the company's most recent Annual Report on Form 10-K and other publicly available information regarding the company. Copies of such information are available from the company upon request. Such publicly available information sets forth many risks and uncertainties related to the company's business and technology. Forward-looking statements often contain such words like "estimate," "anticipate," "believe," "plan" or "expect." The company disclaims any intent or obligation to update these forward-looking statements. Final review decisions made by the FDA and other regulatory agencies concerning clinical trial results are unpredictable and outside the influence and/or control of the company.